A Phase 3 interventional study of Dolutegravir (DTG) and Lamivudine (3TC) in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 105 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-07.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.
Among the 132 studies testing lamivudine in HIV Infections, this one is the 14th largest by enrollment of the 126 interventional ones that give a count, is one of 2 that started in 2016, is one of 50 in phase 3, and was the 111th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
University College, London
Ages 4 wk–14 yrs
By country, each count listing its studies:
Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 28 · Phase 3 51 · Phase 4 29
First in 1996; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 722 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 154 across the 126 interventional studies. Of the 112 that completed or were terminated, 21 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 132 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 11th largest by enrollment of the 210 interventional ones that give a count, is one of 8 that started in 2016, is one of 65 in phase 3, and was the 171st registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing lamivudine in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 132 studies testing lamivudine in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (tenofovir disoproxil fumarate [TDF]/emtricitabine [FTC] fixed dose combination [FDC]) administered once daily in human immunodeficiency virus (HIV) 1 infected adult participants that have not previously received antiretroviral therapy. The study is designed to demonstrate the non inferior antiviral activity of DTG + 3TC regimen to that of DTG + TDF/FTC FDC and will characterise the long term antiviral activity, tolerability and safety of DTG plus 3TC through Week 148. Approximately, 700 participants will be randomised 1:1 to receive DTG + 3TC or DTG + TDF/FTC FDC. Participants will be stratified by screening HIV 1 ribonucleotide nucleic acid (RNA) levels and by screening CD4+ (cluster of differentiation 4) cell count.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
This study's enrollment of 722 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An eligible female participant should not be pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at Screening and negative urine test at Baseline), not lactating, and at least one of the following conditions applies
Exclusion Criteria
Participants positive for HBV surface antigen (HBsAg) at screening will be excluded Participants negative for HBV core antibody (anti HBs) but positive for anti HBc (negative HBsAg status) and positive for HBV deoxyribose nucleic acid (DNA) will be excluded; however, participants positive for anti HBc (negative HBsAg status) and positive for anti HBs (past and/or current evidence) are immune to HBV and will not be excluded
Treatment with any of the following agents within 28 days of Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the participant no longer derives clinical benefit, or (iv) the participant meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
Drug: Dolutegravir (DTG) · Drug: Lamivudine (3TC)
Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
Drug: Dolutegravir (DTG) · Drug: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
Drug pages: Tenofovir · Emtricitabine
Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel (CMH) weights. Intent-To-Treat Exposed (ITT-E) Population was used which comprised of all randomized participants who received at least one dose of study treatment. Percentage values are rounded off.
Time frame: Week 48
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.
Time frame: Week 24
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.
Time frame: Week 96
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.
Time frame: Week 144
Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144
Time of viral suppression is defined as the first viral load value \<50 c/mL. Nonparametric Kaplan-Meier method was performed. Participants who withdrew for any reason without being suppressed were censored at date of withdrawal. Participants who have not been withdrawn and have not had viral suppression at time of the analysis were censored at last viral load date. Confidence Interval (CI) was estimated using the Brookmeyer-Crowley method.
Time frame: Up to Week 144
CD4+ Cell Counts at Weeks 24 and 48
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.
Time frame: Weeks 24 and 48
CD4+ Cell Counts at Week 96
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.
Time frame: Week 96
CD4+ Cell Counts at Week 144
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.
Time frame: Week 144
Changes From Baseline in CD4+ Cell Counts at Week 24 and 48
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted least mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.
Time frame: Baseline and Weeks 24, 48
Changes From Baseline in CD4+ Cell Counts at Week 96
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.
Time frame: Baseline and Week 96
Changes From Baseline in CD4+ Cell Counts at Week 144
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.
Time frame: Baseline and Week 144
Number of Participants With HIV-1 Disease Progression up to Week 144
HIV-associated conditions were recorded during the study and was assessed according to the 2014 Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. Disease progressions summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrolment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrolment to Death. Participants may have more than one indicators of clinical disease progression including death, hence they may contribute to data in more than one categories.
Time frame: Up to Week 144
Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144
Number of participants, who met confirmed virologic withdrawal (CVW) criteria, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI) and/or Nucleoside reverse transcriptase inhibitor (NRTI) was summarized. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data.
Time frame: Up to Week 144
Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144
Number of participants, who met CVW criteria, with treatment emergent phenotypic resistance to INSTI and/or NRTI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results were interpreted through a proprietary algorithm (from Monogram Biosciences) and provides the overall susceptibility of the drugs (DTG, 3TC, Abacavir \[ABC\], elvitegravir \[EGV\], raltegravir \[RAL\], zidovudine \[AZT\], stavudine \[D4T\], didanosine \[DDI\]), emtricitabine \[FTC\], tenofovir disiproxil fumarate \[TDF\]). Partially sensitive and resistant cells were considered resistant in this analysis. The Viral Phenotypic Population comprised of all participants in the ITT-E population who have available on-treatment phenotypic resistance data.
Time frame: Up to Week 144
Number of Participants With Any Adverse Event (AE) and Serious AE (SAE) up to Week 148
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or protocol-defined event associated with liver injury and impaired liver function were categorized as SAE. Safety Population was used which comprised of all participants who received at least one dose of study treatment.
Time frame: Up to Week 148
Number of Participants With AEs by Maximum Severity Grades up to Week 148
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
Time frame: Up to Week 148
Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 148
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5. (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with drug related AEs and drug related AEs by by maximum grade have been presented.
Time frame: Up to Week 148
Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144
Blood samples were collected up to Week 144 for assessment of hemoglobin, leukocytes, neutrophils and platelet count. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the listed hematology parameters have been presented.
Time frame: Up to Week 144
Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144
Blood samples were collected up to Week 144 for assessment of Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin, Carbon dioxide (CO2), Cholesterol, Creatine kinase (CK), Creatinine, Direct Bilirubin, Glomerular filtration rate (GFR), Hypercalcemia, Hyperglycemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Low density lipid (LDL) Cholesterol, Lactate Dehydrogenase, Lipase, Phosphate, and Triglycerides. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent chemistry toxicities in any of the chemistry parameters have been presented.
Time frame: Up to Week 144
Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.
Time frame: Up to Weeks 24, 48 and 96
Number of Participants Who Discontinue Treatment Due to AEs Over Week 144
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.
Time frame: Up to Week 144
Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C and Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Weeks 24, 48
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.
Time frame: Baseline and at Week 96
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.
Time frame: Baseline and at Week 144
Change From Baseline in Renal Biomarker-Serum RBP at Week 96
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Week 96
Change From Baseline in Renal Biomarker-Serum RBP at Week 144
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Week 144
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48
Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI (GFR-cystatin C adjusted) and Serum or Plasma GFR from creatinine adjusted using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Weeks 24, 48
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96
Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Week 96
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144
Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Week 144
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48
Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Weeks 24, 48
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96
Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.
Time frame: Baseline and at Week 96
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144
Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.
Time frame: Baseline and at Week 144
Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48
Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Geometric mean ratio and 95% CI of geometric mean ratio have been presented. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and Weeks 24, 48
Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96
Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and Week 96
Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144
Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.
Time frame: Baseline and at Week 144
Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48
Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
Time frame: Baseline (Day 1) and at Weeks 24, 48
Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96
Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and at Week 96
Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144
Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and at Week 144
Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48
Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
Time frame: Baseline and at Weeks 24, 48
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96
Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
Time frame: Baseline and at Week 96
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144
Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
Time frame: Baseline and at Week 144
Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma High Density Lipoprotein (HDL) Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48
Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value is defined as the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).
Time frame: Baseline and at Weeks 24, 48
Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96
Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and at Week 96
Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144
Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and at Week 144
Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48
Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value). Lipid last observation carried forwarded (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Participants on lipid-lowering agents at Baseline were excluded.
Time frame: Baseline (Day 1) and at Weeks 24, 48
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96
Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and at Week 96
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144
Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and at Week 144
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48
Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24 and 48 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 48 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.
Time frame: Weeks 24 and 48
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96
Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 96 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 96 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.
Time frame: Week 96
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144
Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 144 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 144 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.
Time frame: Week 144
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000 c/mL) and Race (White, African American/African heritage (H.), Asian other). Percentage values are rounded-off.
Time frame: Week 24
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.
Time frame: Week 48
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.
Time frame: Week 96
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.
Time frame: Week 144
Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
Time frame: Baseline (Day 1) and Week 24
Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from Analysis of Covariance (ANCOVA) model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
Time frame: Baseline (Day 1) and Week 48
Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
Time frame: Baseline (Day 1) and Week 96
Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
Time frame: Baseline (Day 1) and Week 144
Change From Baseline in European Quality of Life [EuroQoL] - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 4, 24, 48
Change From Baseline in EQ-5D-5L Utility Score at Week 96
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and Week 96
Change From Baseline in EQ-5D-5L Utility Score at Week 144
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and Week 144
Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24, 48
EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 4, 24, 48
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96
EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and Week 96
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144
EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
Time frame: Baseline (Day 1) and Week 144
This study is a Phase 3, randomized, double-blind, parallel group, non-inferiority study. The study consisted of double-blind phase, open-label phase and continuation phase.
| Milestone | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase | DTG + 3TC - Open-label Phase | DTG + TDF/FTC - Open-label Phase | DTG + 3TC - Continuation Phase |
|---|---|---|---|---|---|
| Started | 360 | 362 | 0 | 0 | 0 |
| Intent-to-treat exposed | 360 | 359 | 0 | 0 | 0 |
| Completed | 319 | 327 | 0 | 0 | 0 |
| Not completed | 41 | 35 | 0 | 0 | 0 |
| Withdrew: Protocol specific withdrawal criteria | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 9 | 0 | 0 | 0 |
| Withdrew: Physician decision | 3 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 9 | 7 | 0 | 0 | 0 |
| Withdrew: Adverse event | 10 | 6 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 2 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 5 | 3 | 0 | 0 | 0 |
| Withdrew: Randomized, but did not receive treatment | 0 | 3 | 0 | 0 | 0 |
| Milestone | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase | DTG + 3TC - Open-label Phase | DTG + TDF/FTC - Open-label Phase | DTG + 3TC - Continuation Phase |
|---|---|---|---|---|---|
| Started | 0 | 0 | 319 | 327 | 0 |
| Completed | 0 | 0 | 301 | 300 | 0 |
| Not completed | 0 | 0 | 18 | 27 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 6 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 2 | 2 | 0 |
| Withdrew: Protocol-specified withdrawal criteria | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 7 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 3 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 7 | 9 | 0 |
| Milestone | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase | DTG + 3TC - Open-label Phase | DTG + TDF/FTC - Open-label Phase | DTG + 3TC - Continuation Phase |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 252 |
| Completed | 0 | 0 | 0 | 0 | 239 |
| Not completed | 0 | 0 | 0 | 0 | 13 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 5 |
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel (CMH) weights. Intent-To-Treat Exposed (ITT-E) Population was used which comprised of all randomized participants who received at least one dose of study treatment. Percentage values are rounded off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48 | 93 (90.4 to 95.7) | 94 (91.4 to 96.4) |
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24 | 94 (91.4 to 96.4) | 94 (91.4 to 96.4) |
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96 | 88 (84.4 to 91.2) | 90 (86.5 to 92.8) |
Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded off.
| Percentage of participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144 | 84 (80.4 to 87.9) | 84 (80.6 to 88.2) |
Time of viral suppression is defined as the first viral load value \<50 c/mL. Nonparametric Kaplan-Meier method was performed. Participants who withdrew for any reason without being suppressed were censored at date of withdrawal. Participants who have not been withdrawn and have not had viral suppression at time of the analysis were censored at last viral load date. Confidence Interval (CI) was estimated using the Brookmeyer-Crowley method.
| Days | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144 | 29.0 (29.0 to 55.0) | 29.0 (29.0 to 57.0) |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Week 24, n=349,345 | 650.4 ± 257.02 | 633.0 ± 287.37 |
| Week 48, n=337,340 | 688.1 ± 266.39 | 689.8 ± 308.49 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| CD4+ Cell Counts at Week 96 | 734.9 ± 270.82 | 739.9 ± 299.80 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| CD4+ Cell Counts at Week 144 | 763.8 ± 266.61 | 770.4 ± 332.65 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted least mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Week 24, n=349, 345 | 188.8 ± 8.77 | 163.2 ± 9.08 |
| Week 48, n=337, 340 | 225.7 ± 8.94 | 217.2 ± 9.93 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Changes From Baseline in CD4+ Cell Counts at Week 96 | 272.0 ± 10.83 | 264.6 ± 11.18 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Changes From Baseline in CD4+ Cell Counts at Week 144 | 301.7 ± 11.55 | 296.6 ± 13.55 |
HIV-associated conditions were recorded during the study and was assessed according to the 2014 Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. Disease progressions summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrolment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrolment to Death. Participants may have more than one indicators of clinical disease progression including death, hence they may contribute to data in more than one categories.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| No disease progression | 356 | 357 |
| From CDC Stage 1 to CDC Stage 3 Event | 0 | 0 |
| From CDC Stage 2 to CDC Stage 3 Event | 2 | 1 |
| From CDC Stage 3 to New CDC Stage 3 Event | 1 | 0 |
| From CDC Stage 1, 2 or 3 to Death | 2 | 1 |
Number of participants, who met confirmed virologic withdrawal (CVW) criteria, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI) and/or Nucleoside reverse transcriptase inhibitor (NRTI) was summarized. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| INSTI Mutations | 0 | 0 |
| Major mutations of the NRTI | 0 | 0 |
Number of participants, who met CVW criteria, with treatment emergent phenotypic resistance to INSTI and/or NRTI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results were interpreted through a proprietary algorithm (from Monogram Biosciences) and provides the overall susceptibility of the drugs (DTG, 3TC, Abacavir \[ABC\], elvitegravir \[EGV\], raltegravir \[RAL\], zidovudine \[AZT\], stavudine \[D4T\], didanosine \[DDI\]), emtricitabine \[FTC\], tenofovir disiproxil fumarate \[TDF\]). Partially sensitive and resistant cells were considered resistant in this analysis. The Viral Phenotypic Population comprised of all participants in the ITT-E population who have available on-treatment phenotypic resistance data.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| INSTI, DTG, Sensitive, n=7,2 | 7 | 2 |
| INSTI, DTG, Resistant, n=7,2 | 0 | 0 |
| INSTI, EGV, Sensitive, n=7,2 | 7 | 2 |
| INSTI, EGV, Resistant, n=7,2 | 0 | 0 |
| INSTI, RAL, Sensitive, n=7,2 | 7 | 2 |
| INSTI, RAL, Resistant, n=7,2 | 0 | 0 |
| NRTI, 3TC, Sensitive, n=7,3 | 7 | 3 |
| NRTI, 3TC, Resistant, n=7,3 | 0 | 0 |
| NRTI, ABC, Sensitive, n=7,3 | 7 | 3 |
| NRTI, ABC, Resistant, n=7,3 | 0 | 0 |
| NRTI, AZT, Sensitive, n=7,3 | 7 | 3 |
| NRTI, AZT, Resistant, n=7,3 | 0 | 0 |
| NRTI, D4T, Sensitive, n=7,3 | 7 | 3 |
| NRTI, D4T, Resistant, n=7,3 | 0 | 0 |
| NRTI, DDI, Sensitive, n=7,3 | 7 | 3 |
| NRTI, DDI, Resistant, n=7,3 | 0 | 0 |
| NRTI, FTC, Sensitive, n=7,3 | 7 | 3 |
| NRTI, FTC, Resistant, n=7,3 | 0 | 0 |
| NRTI, TDF, Sensitive, n=7,3 | 7 | 3 |
| NRTI, TDF, Resistant, n=7,3 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or protocol-defined event associated with liver injury and impaired liver function were categorized as SAE. Safety Population was used which comprised of all participants who received at least one dose of study treatment.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Any AE | 306 | 309 |
| Any SAE | 39 | 47 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Grade 1 AEs | 54 | 54 |
| Grade 2 AEs | 211 | 205 |
| Grade 3 AEs | 32 | 43 |
| Grade 4 AEs | 7 | 6 |
| Grade 5 AEs | 2 | 1 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5. (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with drug related AEs and drug related AEs by by maximum grade have been presented.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Any drug related AE | 69 | 91 |
| Drug related AEs with maximum toxicity Grade 1 | 37 | 53 |
| Drug related AEs with maximum toxicity Grade 2 | 26 | 29 |
| Drug related AEs with maximum toxicity Grade 3 | 5 | 8 |
| Drug related AEs with maximum toxicity Grade 4 | 1 | 1 |
| Drug related AEs with maximum toxicity Grade 5 | 0 | 0 |
Blood samples were collected up to Week 144 for assessment of hemoglobin, leukocytes, neutrophils and platelet count. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the listed hematology parameters have been presented.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Hemoglobin, Grades 1 to 4 | 8 | 10 |
| Hemoglobin, Grades 2 to 4 | 6 | 6 |
| Hemoglobin, Grades 3 to 4 | 2 | 1 |
| Hemoglobin, Grade 1 | 2 | 4 |
| Hemoglobin, Grade 2 | 4 | 5 |
| Hemoglobin, Grade 3 | 1 | 1 |
| Hemoglobin, Grade 4 | 1 | 0 |
| Leukocytes, Grades 1 to 4 | 5 | 5 |
| Leukocytes, Grades 2 to 4 | 1 | 0 |
| Leukocytes, Grades 3 to 4 | 0 | 0 |
| Leukocytes, Grade 1 | 4 | 5 |
| Leukocytes, Grade 2 | 1 | 0 |
| Leukocytes, Grade 3 | 0 | 0 |
| Leukocytes, Grade 4 | 0 | 0 |
| Neutrophils, Grades 1 to 4 | 23 | 7 |
| Neutrophils, Grades 2 to 4 | 8 | 3 |
| Neutrophils, Grades 3 to 4 | 4 | 1 |
| Neutrophils, Grade 1 | 15 | 4 |
| Neutrophils, Grade 2 | 4 | 2 |
| Neutrophils, Grade 3 | 2 | 1 |
| Neutrophils, Grade 4 | 2 | 0 |
| Platelets, Grades 1 to 4 | 13 | 9 |
| Platelets, Grades 2 to 4 | 5 | 5 |
| Platelets, Grades 3 to 4 | 0 | 0 |
| Platelets, Grade 1 | 8 | 4 |
| Platelets, Grade 2 | 5 | 5 |
| Platelets, Grade 3 | 0 | 0 |
| Platelets, Grade 4 | 0 | 0 |
Blood samples were collected up to Week 144 for assessment of Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin, Carbon dioxide (CO2), Cholesterol, Creatine kinase (CK), Creatinine, Direct Bilirubin, Glomerular filtration rate (GFR), Hypercalcemia, Hyperglycemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Low density lipid (LDL) Cholesterol, Lactate Dehydrogenase, Lipase, Phosphate, and Triglycerides. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent chemistry toxicities in any of the chemistry parameters have been presented.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| ALT, Grades 1 to 4 | 77 | 71 |
| ALT, Grades 2 to 4 | 30 | 29 |
| ALT, Grades 3 to 4 | 13 | 15 |
| ALT, Grade 1 | 47 | 42 |
| ALT, Grade 2 | 17 | 14 |
| ALT, Grade 3 | 6 | 8 |
| ALT, Grade 4 | 7 | 7 |
| Albumin, Grades 1 to 4 | 2 | 1 |
| Albumin, Grades 2 to 4 | 2 | 1 |
| Albumin, Grades 3 to 4 | 0 | 1 |
| Albumin, Grade 1 | 0 | 0 |
| Albumin, Grade 2 | 2 | 0 |
| Albumin, Grade 3 | 0 | 1 |
| Albumin, Grade 4 | 0 | 0 |
| ALP, Grades 1 to 4 | 10 | 17 |
| ALP, Grades 2 to 4 | 2 | 3 |
| ALP, Grades 3 to 4 | 0 | 1 |
| ALP, Grade 1 | 8 | 14 |
| ALP, Grade 2 | 2 | 2 |
| ALP, Grade 3 | 0 | 1 |
| ALP, Grade 4 | 0 | 0 |
| AST, Grades 1 to 4 | 71 | 83 |
| AST, Grades 2 to 4 | 30 | 32 |
| AST, Grades 3 to 4 | 15 | 14 |
| AST, Grade 1 | 41 | 51 |
| AST, Grade 2 | 15 | 18 |
| AST, Grade 3 | 8 | 11 |
| AST, Grade 4 | 7 | 3 |
| Bilirubin, Grades 1 to 4 | 46 | 56 |
| Bilirubin, Grades 2 to 4 | 13 | 16 |
| Bilirubin, Grades 3 to 4 | 4 | 3 |
| Bilirubin, Grade 1 | 33 | 40 |
| Bilirubin, Grade 2 | 9 | 13 |
| Bilirubin, Grade 3 | 0 | 2 |
| Bilirubin, Grade 4 | 4 | 1 |
| CO2, Grades 1 to 4 | 111 | 111 |
| CO2, Grades 2 to 4 | 10 | 4 |
| CO2, Grades 3 to 4 | 0 | 0 |
| CO2, Grade 1 | 101 | 107 |
| CO2, Grade 2 | 10 | 4 |
| CO2, Grade 3 | 0 | 0 |
| CO2, Grade 4 | 0 | 0 |
| Cholesterol, Grades 1 to 4 | 98 | 50 |
| Cholesterol, Grades 2 to 4 | 23 | 12 |
| Cholesterol, Grades 3 to 4 | 1 | 0 |
| Cholesterol, Grade 1 | 75 | 38 |
| Cholesterol, Grade 2 | 22 | 12 |
| Cholesterol, Grade 3 | 1 | 0 |
| Cholesterol, Grade 4 | 0 | 0 |
| CK, Grades 1 to 4 | 91 | 83 |
| CK, Grades 2 to 4 | 49 | 47 |
| CK, Grades 3 to 4 | 29 | 28 |
| CK, Grade 1 | 42 | 36 |
| CK, Grade 2 | 20 | 19 |
| CK, Grade 3 | 11 | 11 |
| CK, Grade 4 | 18 | 17 |
| Creatinine, Grades 1 to 4 | 18 | 28 |
| Creatinine, Grades 2 to 4 | 5 | 2 |
| Creatinine, Grades 3 to 4 | 0 | 1 |
| Creatinine, Grade 1 | 13 | 26 |
| Creatinine, Grade 2 | 5 | 1 |
| Creatinine, Grade 3 | 0 | 1 |
| Creatinine, Grade 4 | 0 | 0 |
| Direct Bilirubin, Grades 1 to 4 | 11 | 10 |
| Direct Bilirubin, Grades 2 to 4 | 11 | 10 |
| Direct Bilirubin, Grades 3 to 4 | 11 | 10 |
| Direct Bilirubin, Grade 1 | 0 | 0 |
| Direct Bilirubin, Grade 2 | 0 | 0 |
| Direct Bilirubin, Grade 3 | 11 | 10 |
| Direct Bilirubin, Grade 4 | 0 | 0 |
| GFR, Grades 1 to 4 | 198 | 219 |
| GFR, Grades 2 to 4 | 198 | 219 |
| GFR, Grades 3 to 4 | 20 | 29 |
| GFR, Grade 1 | 0 | 0 |
| GFR, Grade 2 | 178 | 190 |
| GFR, Grade 3 | 20 | 28 |
| GFR, Grade 4 | 0 | 1 |
| Hypercalcaemia, Grades 1 to 4 | 4 | 5 |
| Hypercalcaemia, Grades 2 to 4 | 0 | 1 |
| Hypercalcaemia, Grades 3 to 4 | 0 | 1 |
| Hypercalcemia, Grade 1 | 4 | 4 |
| Hypercalcaemia, Grade 2 | 0 | 0 |
| Hypercalcaemia, Grade 3 | 0 | 0 |
| Hypercalcaemia, Grade 4 | 0 | 1 |
| Hyperglycaemia, Grades 1 to 4 | 106 | 86 |
| Hyperglycaemia, Grades 2 to 4 | 49 | 38 |
| Hyperglycaemia, Grades 3 to 4 | 3 | 3 |
| Hyperglycaemia, Grade 1 | 57 | 48 |
| Hyperglycaemia, Grade 2 | 46 | 35 |
| Hyperglycaemia, Grade 3 | 2 | 2 |
| Hyperglycaemia, Grade 4 | 1 | 1 |
| Hyperkalemia, Grades 1 to 4 | 7 | 7 |
| Hyperkalemia, Grades 2 to 4 | 2 | 1 |
| Hyperkalemia, Grades 3 to 4 | 1 | 1 |
| Hyperkalemia, Grade 1 | 5 | 6 |
| Hyperkalemia, Grade 2 | 1 | 0 |
| Hyperkalemia, Grade 3 | 0 | 1 |
| Hyperkalemia, Grade 4 | 1 | 0 |
| Hypernatremia, Grades 1 to 4 | 4 | 7 |
| Hypernatremia, Grades 2 to 4 | 1 | 0 |
| Hypernatremia, Grades 3 to 4 | 0 | 0 |
| Hypernatremia, Grade 1 | 3 | 7 |
| Hypernatremia, Grade 2 | 1 | 0 |
| Hypernatremia, Grade 3 | 0 | 0 |
| Hypernatremia, Grade 4 | 0 | 0 |
| Hypocalcaemia, Grades 1 to 4 | 17 | 21 |
| Hypocalcaemia, Grades 2 to 4 | 6 | 11 |
| Hypocalcaemia, Grades 3 to 4 | 1 | 3 |
| Hypocalcaemia, Grade 1 | 11 | 10 |
| Hypocalcaemia, Grade 2 | 5 | 8 |
| Hypocalcaemia, Grade 3 | 1 | 2 |
| Hypocalcaemia, Grade 4 | 0 | 1 |
| Hypoglycaemia, Grades 1 to 4 | 22 | 21 |
| Hypoglycaemia, Grades 2 to 4 | 6 | 5 |
| Hypoglycaemia, Grades 3 to 4 | 4 | 1 |
| Hypoglycaemia, Grade 1 | 16 | 16 |
| Hypoglycaemia, Grade 2 | 2 | 4 |
| Hypoglycaemia, Grade 3 | 3 | 0 |
| Hypoglycaemia, Grade 4 | 1 | 1 |
| Hypokalemia, Grades 1 to 4 | 9 | 5 |
| Hypokalemia, Grades 2 to 4 | 0 | 1 |
| Hypokalemia, Grades 3 to 4 | 0 | 0 |
| Hypokalemia, Grade 1 | 9 | 4 |
| Hypokalemia, Grade 2 | 0 | 1 |
| Hypokalemia, Grade 3 | 0 | 0 |
| Hypokalemia, Grade 4 | 0 | 0 |
| Hyponatremia, Grades 1 to 4 | 23 | 22 |
| Hyponatremia, Grades 2 to 4 | 0 | 3 |
| Hyponatremia, Grades 3 to 4 | 0 | 1 |
| Hyponatremia, Grade 1 | 23 | 19 |
| Hyponatremia, Grade 2 | 0 | 2 |
| Hyponatremia, Grade 3 | 0 | 0 |
| Hyponatremia, Grade 4 | 0 | 1 |
| LDL Cholesterol, Grades 1 to 4 | 66 | 40 |
| LDL Cholesterol, Grades 2 to 4 | 21 | 13 |
| LDL Cholesterol, Grades 3 to 4 | 6 | 2 |
| LDL Cholesterol, Grade 1 | 45 | 27 |
| LDL Cholesterol, Grade 2 | 15 | 11 |
| LDL Cholesterol, Grade 3 | 6 | 2 |
| LDL Cholesterol, Grade 4 | 0 | 0 |
| Lactate Dehydrogenase, Grades 1 to 4 | 4 | 2 |
| Lactate Dehydrogenase, Grades 2 to 4 | 3 | 0 |
| Lactate Dehydrogenase, Grades 3 to 4 | 0 | 0 |
| Lactate Dehydrogenase, Grade 1 | 1 | 2 |
| Lactate Dehydrogenase, Grade 2 | 3 | 0 |
| Lactate Dehydrogenase, Grade 3 | 0 | 0 |
| Lactate Dehydrogenase, Grade 4 | 0 | 0 |
| Lipase, Grades 1 to 4 | 72 | 81 |
| Lipase, Grades 2 to 4 | 37 | 43 |
| Lipase, Grades 3 to 4 | 9 | 17 |
| Lipase, Grade 1 | 35 | 38 |
| Lipase, Grade 2 | 28 | 26 |
| Lipase, Grade 3 | 6 | 13 |
| Lipase, Grade 4 | 3 | 4 |
| Phosphate, Grades 1 to 4 | 75 | 78 |
| Phosphate, Grades 2 to 4 | 50 | 51 |
| Phosphate, Grades 3 to 4 | 7 | 7 |
| Phosphate, Grade 1 | 25 | 27 |
| Phosphate, Grade 2 | 43 | 44 |
| Phosphate, Grade 3 | 7 | 7 |
| Phosphate, Grade 4 | 0 | 0 |
| Triglycerides, Grades 1 to 4 | 89 | 75 |
| Triglycerides, Grades 2 to 4 | 22 | 15 |
| Triglycerides, Grades 3 to 4 | 4 | 1 |
| Triglycerides, Grade 1 | 67 | 60 |
| Triglycerides, Grade 2 | 18 | 14 |
| Triglycerides, Grade 3 | 4 | 1 |
| Triglycerides, Grade 4 | 0 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.
| Participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Week 24 | 6 | 4 |
| Week 48 | 8 | 8 |
| Week 96 | 10 | 12 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.
| Participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Number of Participants Who Discontinue Treatment Due to AEs Over Week 144 | 13 | 16 |
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C and Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Milligrams per Liter (mg/L) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Serum Cystatin C, Week 24, n=345,345 | -0.04 ± 0.005 | 0.00 ± 0.005 |
| Serum Cystatin C, Week 48, n=335,336 | -0.05 ± 0.005 | -0.04 ± 0.006 |
| Serum RBP, Week 24, n=345,343 | 1.2 ± 0.42 | 1.4 ± 0.48 |
| Serum RBP, Week 48, n=334, 334 | 0.6 ± 0.45 | -0.1 ± 0.42 |
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.
| mg/L | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96 | -0.09 ± 0.006 | -0.08 ± 0.005 |
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.
| mg/L | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144 | -0.11 ± 0.005 | -0.08 ± 0.006 |
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Microgram per millimoles (ug/mmol) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Change From Baseline in Renal Biomarker-Serum RBP at Week 96 | 0.557 ± 12.7139 | 2.483 ± 23.9105 |
Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment. Change from Baseline was defined as value at indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Microgram per millimoles (ug/mmol) | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Change From Baseline in Renal Biomarker-Serum RBP at Week 144 | 0.560 ± 9.5962 | 3.813 ± 10.8115 |
Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI (GFR-cystatin C adjusted) and Serum or Plasma GFR from creatinine adjusted using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Milliliter/minute/1.73 meter^2 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| GFR Cystatin C adjusted, Week 24, n=345,345 | 3.8 ± 0.66 | 0.2 ± 0.65 |
| GFR Cystatin C adjusted, Week 48, n=335,336 | 5.4 ± 0.64 | 3.6 ± 0.64 |
| GFR creatinine adjusted, Week 24, n=346,344 | -12.0 ± 0.64 | -15.4 ± 0.59 |
| GFR creatinine adjusted, Week 48, n=335, 337 | -12.1 ± 0.60 | -15.4 ± 0.61 |
Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Milliliter/minute/1.73 meter^2 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| GFR Cystatin C adjusted, Week 96, n=316,326 | 9.1 ± 18.75 | 9.5 ± 13.95 |
| GFR creatinine adjusted, Week 96, n=315,325 | -14.2 ± 12.69 | -17.5 ± 11.57 |
Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment. Change from Baseline was defined as value at the indicated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Milliliter/minute/1.73 meter^2 | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| GFR Cystatin C adjusted, Week 144, n=301,304 | 10.3 ± 18.82 | 10.1 ± 15.50 |
| GFR creatinine adjusted, Week 144, n=292,292 | -15.5 ± 12.56 | -18.2 ± 11.73 |
Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Micromoles per Liter (umol/L) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Serum or Plasma Creatinine, Week 24, n=346, 344 | 10.51 ± 0.548 | 13.53 ± 0.507 |
| Serum or Plasma Creatinine, Week 48, n=335, 337 | 10.32 ± 0.519 | 13.44 ± 0.540 |
Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.
| Micromoles per Liter (umol/L) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96 | 11.71 ± 0.563 | 14.75 ± 0.526 |
Blood and samples were collected to perform evaluation of renal biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the the latest pre-dose assessment. Change from Baseline was calculated as value at the inidcated time point minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error has been presented.
| Micromoles per Liter (umol/L) | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144 | 12.28 ± 0.613 | 15.14 ± 0.583 |
Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Geometric mean ratio and 95% CI of geometric mean ratio have been presented. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Ratio | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Serum B2M, Week 24, n=344,346 | 0.809 (0.794 to 0.824) | 0.882 (0.867 to 0.898) |
| Serum B2M, Week 48, n=335,336 | 0.811 (0.796 to 0.827) | 0.887 (0.871 to 0.904) |
| Urine B2M, Week 24, n=124,106 | 0.844 (0.755 to 0.944) | 1.129 (0.974 to 1.309) |
| Urine B2M, Week 48, n=109, 103 | 0.917 (0.804 to 1.046) | 1.323 (1.066 to 1.642) |
| Urine Albumin/Creatinine, Week 24, n=259, 251 | 0.907 (0.844 to 0.976) | 1.021 (0.940 to 1.109) |
| Urine Albumin/Creatinine , Week 48, n=249, 240 | 0.911 (0.835 to 0.994) | 0.971 (0.891 to 1.058) |
| Urine B2M/Urine Creatinine , Week 24, n=122, 104 | 0.880 (0.779 to 0.993) | 1.126 (0.988 to 1.282) |
| Urine B2M/Urine Creatinine , Week 48, n=108, 103 | 0.969 (0.854 to 1.099) | 1.307 (1.077 to 1.586) |
| Urine Phosphate, Week 24, n=343, 340 | 1.041 (0.955 to 1.134) | 1.063 (0.978 to 1.157) |
| Urine Phosphate, Week 48, n=335, 332 | 1.121 (1.031 to 1.220) | 1.056 (0.974 to 1.144) |
| Urine Protein/Creatinine, Week 24, n=263,279 | 0.818 (0.779 to 0.859) | 0.991 (0.941 to 1.043) |
| Urine Protein/Creatinine , Week 48, n=259, 261 | 0.866 (0.818 to 0.917) | 1.007 (0.954 to 1.062) |
| Urine RBP 4, Week 24, n=340, 338 | 0.656 (0.591 to 0.729) | 0.824 (0.738 to 0.921) |
| Urine RBP 4, Week 48, n=333, 331 | 0.740 (0.666 to 0.822) | 0.819 (0.730 to 0.919) |
| Urine RBP 4/Urine Creatinine, Week 24, n=338, 335 | 0.670 (0.614 to 0.730) | 0.811 (0.741 to 0.888) |
| Urine RBP 4/Urine Creatinine, Week 48, n=331, 328 | 0.749 (0.689 to 0.814) | 0.844 (0.774 to 0.920) |
Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Ratio | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Urine Albumin/Creatinine, Week 96, n=239, 243 | 0.939 (0.861 to 1.023) | 0.997 (0.914 to 1.087) |
| Urine B2M/Urine Creatinine, Week 96, n=101, 96 | 0.844 (0.757 to 0.941) | 1.259 (1.055 to 1.503) |
| Urine Phosphate, Week 96, n=316, 322 | 1.156 (1.064 to 1.256) | 1.069 (0.988 to 1.156) |
| Urine Protein/Creatinine, Week 96, n=251, 261 | 0.887 (0.836 to 0.942) | 1.016 (0.963 to 1.072) |
| Urine RBP 4/Urine Creatinine, Week 96, n=314, 318 | 1.030 (0.953 to 1.113) | 1.287 (1.189 to 1.393) |
Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers: Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine. Baseline value was the latest pre-dose assessment. Change from Baseline was performed on log-transformed data. Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Biomarkers were Adjusted for treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, loge transformed Baseline biomarker value, treatment and visit interaction, and loge transformed Baseline biomarker value and visit interaction; with visit as the repeated factor.
| Ratio | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Urine Albumin/Creatinine, Week 144, n=230, 221 | 1.036 (0.943 to 1.138) | 1.067 (0.973 to 1.169) |
| Urine B2M/Urine Creatinine, Week 144, n=108, 93 | 0.872 (0.792 to 0.960) | 1.494 (1.266 to 1.762) |
| Urine Phosphate, Week 144, n=301, 301 | 1.083 (1.000 to 1.174) | 1.084 (0.999 to 1.175) |
| Urine Protein/Creatinine, Week 144, n=236, 246 | 0.999 (0.947 to 1.054) | 1.180 (1.118 to 1.245) |
| Urine RBP 4/Urine Creatinine, Week 144, n=294, 289 | 1.159 (1.083 to 1.240) | 1.567 (1.451 to 1.694) |
Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
| Micrograms per Liter (ug/L) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Bone-ALP, Week 24, n=345, 346 | 0.72 ± 0.171 | 3.38 ± 0.244 |
| Bone-ALP, Week 48, n=334, 337 | 1.24 ± 0.198 | 4.33 ± 0.268 |
| Serum Osteocalcin, Week 24, n=345, 346 | 2.13 ± 0.321 | 6.80 ± 0.368 |
| Serum Osteocalcin, Week 48, n=335, 336 | 0.40 ± 0.326 | 6.30 ± 0.384 |
| PINP, Week 24, n=344, 346 | 1.7 ± 0.95 | 15.2 ± 1.12 |
| PINP, Week 48, n=335, 337 | 0.4 ± 0.79 | 13.3 ± 1.06 |
| CTX-1, Week 24, n=342, 342 | 0.1541 ± 0.01247 | 0.2812 ± 0.01406 |
| CTX-1, Week 48, n=332, 333 | 0.1345 ± 0.01496 | 0.3388 ± 0.01983 |
Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
| Micrograms per Liter (ug/L) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Bone-ALP, Week 96, n=315, 326 | 0.26 ± 0.188 | 2.39 ± 0.234 |
| Serum Osteocalcin, Week 96, n=315, 326 | 0.13 ± 0.286 | 3.90 ± 0.368 |
| PINP, Week 96, n=315, 325 | 7.0 ± 1.37 | 19.5 ± 1.66 |
| CTX-1, Week 96, n=311, 318 | 0.0604 ± 0.01056 | 0.1787 ± 0.01403 |
Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type CTX-1. Adjusted mean is the estimated mean change from Baseline in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
| Micrograms per Liter (ug/L) | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Bone-ALP, Week 144, n=302, 305 | -0.25 ± 0.156 | 1.88 ± 0.266 |
| Serum Osteocalcin, Week 144, n=300, 304 | -1.02 ± 0.280 | 2.87 ± 0.412 |
| PINP, Week 144, n=299, 300 | -0.1 ± 0.94 | 9.4 ± 1.39 |
| CTX-1, Week 144, n=291, 298 | 0.0505 ± 0.01154 | 0.1868 ± 0.01516 |
Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
| Nanomoles per Liter (nmol/L) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Serum Vitamin D, Week 24, n=346, 344 | 11.2 ± 1.08 | 15.4 ± 1.33 |
| Serum Vitamin D, Week 48, n=336, 335 | 0.3 ± 0.92 | 0.4 ± 1.01 |
Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
| Nanomoles per Liter (nmol/L) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96 | -1.7 ± 1.01 | 1.3 ± 1.09 |
Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Baseline value is defined as the latest pre-dose assessment. Change from Baseline was calculated as value at the indicated time point minus Baseline value.
| Nanomoles per Liter (nmol/L) | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144 | 1.1 ± 1.20 | 1.4 ± 1.22 |
Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value is defined as the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).
| Percentage change | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Serum or Plasma Cholesterol, Week 24, n=298, 310 | 5.0 ± 16.85 | -4.5 ± 15.44 |
| Serum or Plasma Cholesterol, Week 48, n=298, 307 | 9.3 ± 17.10 | -3.3 ± 14.61 |
| HDL Cholesterol, Direct, Week 24, n=299, 310 | 13.9 ± 25.17 | 7.2 ± 32.22 |
| HDL Cholesterol, Direct, Week 48, n=299, 307 | 15.3 ± 23.75 | 4.0 ± 21.86 |
| LDL Cholesterol, Week 24, n=298, 309 | 3.8 ± 25.85 | -7.8 ± 21.13 |
| LDL Cholesterol, Week 48, n=297, 307 | 10.7 ± 27.54 | -4.1 ± 20.39 |
| Triglycerides,Week 24, n=299, 310 | 7.0 ± 40.45 | 0.5 ± 44.01 |
| Triglycerides, Week 48, n=299, 307 | 7.3 ± 46.92 | -0.3 ± 49.22 |
Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
| Millimoles per liter | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Serum or Plasma Cholesterol, Week 96, n=270, 289 | 0.345 ± 0.0356 | -0.132 ± 0.0375 |
| HDL Cholesterol, Direct, Week 96, n=271, 289 | 0.185 ± 0.0160 | 0.071 ± 0.0136 |
| LDL Cholesterol, Week 96, n=270, 289 | 0.139 ± 0.0308 | -0.160 ± 0.0304 |
| Triglycerides, Week 96, n=271, 289 | 0.105 ± 0.0488 | -0.102 ± 0.0365 |
Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
| Millimoles per liter | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Serum or Plasma Cholesterol, Week 144, n=263, 278 | 0.360 ± 0.0432 | -0.015 ± 0.0394 |
| HDL Cholesterol, Direct, Week 144, n=264, 278 | 0.180 ± 0.0162 | 0.093 ± 0.0136 |
| LDL Cholesterol, Week 144, n=263, 278 | 0.143 ± 0.0357 | -0.085 ± 0.0333 |
| Triglycerides, Week 144, n=264, 278 | 0.078 ± 0.0448 | -0.057 ± 0.0430 |
Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value). Lipid last observation carried forwarded (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Participants on lipid-lowering agents at Baseline were excluded.
| Percentage change | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Total/HDL Cholesterol Ratio, Week 24, n=298, 310 | -4.4 ± 22.53 | -7.5 ± 17.90 |
| Total/HDL Cholesterol Ratio, Week 48, n=298, 307 | -2.8 ± 17.86 | -4.5 ± 18.25 |
Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
| Ratio | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96 | -0.113 ± 0.1552 | -0.395 ± 0.0473 |
Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.
| Ratio | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144 | -0.245 ± 0.0545 | -0.359 ± 0.0533 |
Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24 and 48 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 48 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Week 24, n=313, 320 | 4 | 0 |
| Week 48, n=324, 332 | 4 | 2 |
Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 96 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 96 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96 | 6 | 2 |
Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 144 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 144 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded-off.
| Percentage of participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144 | 6 | 4 |
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000 c/mL) and Race (White, African American/African heritage (H.), Asian other). Percentage values are rounded-off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Baseline CD4+ cell count Group-1, <=200,n=32,26 | 78 | 92 |
| Baseline CD4+ cell count Group-1, >200,n=328,333 | 95 | 94 |
| Female, n=54, 46 | 93 | 89 |
| Male, n=306, 313 | 94 | 95 |
| Age, <35,n= 209, 203 | 93 | 94 |
| Age, 35 to <50,n=115, 122 | 96 | 94 |
| Age, >=50, n=36, 34 | 94 | 91 |
| Baseline plasma HIV-1 RNA, <=100000,n=294,282 | 94 | 95 |
| Baseline plasma HIV-1 RNA, >100000,n=66, 77 | 92 | 90 |
| Race, White, n=240, 252 | 95 | 95 |
| Race, African American/African H., n=51, 35 | 90 | 89 |
| Race, Asian, n=34, 30 | 97 | 90 |
| Race, Other, n=35, 42 | 89 | 93 |
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3 for group-1), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Baseline CD4+ cell count Group-1, <=200,n=32, 26 | 78 | 96 |
| Baseline CD4+ cell count Group-1, >200,n=328,333 | 95 | 94 |
| Female, n=54, 46 | 89 | 87 |
| Male, n=306, 313 | 94 | 95 |
| Age, <35,n= 209,203 | 92 | 94 |
| Age, 35 to <50,n=115, 122 | 97 | 94 |
| Age, >=50, n=36, 34 | 89 | 94 |
| Baseline plasma HIV-1 RNA, <=100000,n=294,282 | 92 | 95 |
| Baseline plasma HIV-1 RNA, >100000,n=66, 77 | 97 | 90 |
| Race, White, n=240, 252 | 96 | 96 |
| Race, African American/African H., n=51, 35 | 80 | 86 |
| Race, Asian, n=34, 30 | 97 | 90 |
| Race, Other, n=35, 42 | 86 | 90 |
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.
| Percentage of participants | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Baseline CD4+ cell count, <=200,n=32, 26 | 72 | 85 |
| Baseline CD4+ cell count, >200,n=328,333 | 89 | 90 |
| Female, n=54, 46 | 81 | 85 |
| Male, n=306, 313 | 89 | 90 |
| Age, <35,n= 209, 203 | 88 | 91 |
| Age, 35 to <50,n=115, 122 | 90 | 89 |
| Age, >=50, n=36, 34 | 83 | 88 |
| Baseline plasma HIV-1 RNA, <=100000,n=294, 282 | 88 | 91 |
| Baseline plasma HIV-1 RNA, >100000,n=66, 77 | 86 | 84 |
| Race, White, n=240,252 | 92 | 91 |
| Race, African American/African H., n=51, 35 | 69 | 86 |
| Race, Asian, n=34, 30 | 88 | 90 |
| Race, Other, n=35, 42 | 89 | 83 |
Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded-off.
| Percentage of participants | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Baseline CD4+ cell count, <=200,n=32, 26 | 75 | 69 |
| Baseline CD4+ cell count, >200,n=328,333 | 85 | 86 |
| Female, n=54, 46 | 78 | 83 |
| Male, n=306, 313 | 85 | 85 |
| Age, <35,n= 209, 203 | 83 | 83 |
| Age, 35 to <50,n=115, 122 | 86 | 85 |
| Age, >=50, n=36, 34 | 83 | 88 |
| Baseline plasma HIV-1 RNA, <=100000,n=294, 282 | 84 | 85 |
| Baseline plasma HIV-1 RNA, >100000,n=66, 77 | 86 | 81 |
| Race, White, n=240,252 | 88 | 87 |
| Race, African American/African H., n=51, 35 | 65 | 74 |
| Race, Asian, n=34, 30 | 85 | 83 |
| Race, Other, n=35, 42 | 89 | 79 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Baseline plasma HIV-1 RNA,<=100000, n=283,273 | 186.01 ± 9.948 | 148.21 ± 10.134 |
| Baseline plasma HIV-1 RNA,>100000, n=66,72 | 193.90 ± 20.811 | 220.71 ± 19.814 |
| Baseline CD4+ cell count,<=200, n=29, 26 | 167.95 ± 31.308 | 106.23 ± 32.990 |
| Baseline CD4+ cell count,>200, n=320, 319 | 189.91 ± 9.362 | 167.35 ± 9.362 |
| Age group, <35,n= 201, 193 | 190.12 ± 11.829 | 151.13 ± 12.050 |
| Age group-1, 35 to <50, n=113, 119 | 180.50 ± 15.733 | 190.40 ± 15.404 |
| Age group-1, >=50, n=35, 33 | 198.74 ± 28.411 | 133.21 ± 29.120 |
| Female, n=52, 42 | 213.58 ± 23.225 | 153.92 ± 25.910 |
| Male, n=297, 303 | 183.41 ± 9.719 | 164.18 ± 9.631 |
| Race group, White, n=236, 243 | 186.48 ± 10.932 | 167.44 ± 10.790 |
| Race group, African Am/African H., n=48, 34 | 195.18 ± 24.222 | 151.93 ± 28.784 |
| Race group, Asian, n=33, 28 | 154.03 ± 29.438 | 141.24 ± 31.703 |
| Race group, Other, n=32, 40 | 222.21 ± 29.681 | 160.20 ± 26.627 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from Analysis of Covariance (ANCOVA) model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Baseline plasma HIV-1 RNA,<=100000, n=273,271 | 215.6 ± 10.67 | 208.7 ± 10.71 |
| Baseline plasma HIV-1 RNA,>100000, n=64,69 | 261.8 ± 22.27 | 248.7 ± 21.30 |
| Baseline CD4+ cell count,<=200, n=28, 25 | 210.9 ± 33.42 | 153.2 ± 35.29 |
| Baseline CD4+ cell count,>200, n=309, 315 | 225.8 ± 10.00 | 221.7 ± 9.89 |
| Age group-1, <35,n= 193, 191 | 234.2 ± 12.67 | 201.7 ± 12.72 |
| Age group-1, 35 to <50, n=112, 117 | 212.7 ± 16.59 | 244.2 ± 16.31 |
| Age group-1, >=50, n=32, 32 | 209.1 ± 31.20 | 203.9 ± 31.06 |
| Age group-2, <50,n= 305, 308 | 226.4 ± 10.09 | 217.8 ± 10.03 |
| Age group-2, >=50, n= 32, 32 | 208.5 ± 31.27 | 204.1 ± 31.14 |
| Female, n=48, 41 | 236.2 ± 25.35 | 263.6 ± 27.50 |
| Male, n=289, 299 | 222.8 ± 10.33 | 210.0 ± 10.17 |
| Race group, White, n=230, 244 | 225.5 ± 11.62 | 214.2 ± 11.30 |
| Race group, African Am/African H., n=42, 31 | 201.2 ± 27.16 | 239.0 ± 31.64 |
| Race group, Asian, n=33, 27 | 204.9 ± 30.90 | 189.3 ± 33.88 |
| Race group, Other, n=32, 38 | 270.2 ± 31.15 | 232.6 ± 28.67 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Baseline plasma HIV-1 RNA,<=100000, n=259,260 | 257.9 ± 12.47 | 257.5 ± 12.45 |
| Baseline plasma HIV-1 RNA,>100000, n=59,67 | 312.1 ± 26.37 | 297.4 ± 24.59 |
| Baseline CD4+ cell count,<=200, n=25, 23 | 229.4 ± 40.41 | 202.9 ± 42.00 |
| Baseline CD4+ cell count,>200, n=293, 304 | 272.3 ± 11.73 | 269.4 ± 11.50 |
| Age group-1, <35,n= 186, 187 | 266.0 ± 14.74 | 257.7 ± 14.68 |
| Age group-1, 35 to <50, n=101, 110 | 273.6 ± 19.95 | 286.8 ± 19.22 |
| Age group-1, >=50, n=31, 30 | 265.8 ± 36.14 | 233.1 ± 36.61 |
| Female, n=44, 40 | 312.7 ± 30.12 | 307.6 ± 31.67 |
| Male, n=274, 287 | 261.4 ± 12.07 | 259.3 ± 11.81 |
| Race group, White, n=221, 234 | 272.1 ± 13.49 | 258.3 ± 13.14 |
| Race group, African Am/African H., n=35, 30 | 246.3 ± 33.90 | 303.7 ± 36.61 |
| Race group, Asian, n=31, 27 | 224.0 ± 36.31 | 264.0 ± 38.57 |
| Race group, Other, n=31, 36 | 312.0 ± 36.01 | 278.9 ± 33.56 |
CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.
| Cells/mm^3 | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Baseline plasma HIV-1 RNA,<=100000, n=241,234 | 286.8 ± 14.36 | 277.8 ± 14.58 |
| Baseline plasma HIV-1 RNA,>100000, n=55,58 | 338.2 ± 30.34 | 354.7 ± 29.35 |
| Baseline CD4+ cell count,<=200, n=25, 19 | 264.8 ± 44.91 | 208.9 ± 51.25 |
| Baseline CD4+ cell count,>200, n=271, 273 | 300.3 ± 13.54 | 297.9 ± 13.48 |
| Age group, <35,n=171, 159 | 302.9 ± 17.05 | 277.1 ± 17.65 |
| Age group-1, 35 to <50, n=95, 103 | 292.8 ± 22.82 | 329.2 ± 22.02 |
| Age group-1, >=50, n=30, 30 | 274.1 ± 40.71 | 250.0 ± 40.60 |
| Female, n=40, 37 | 355.0 ± 34.93 | 381.8 ± 36.37 |
| Male, n=256, 255 | 287.7 ± 13.81 | 279.6 ± 13.85 |
| Race group, White, n=202, 211 | 300.0 ± 15.61 | 296.5 ± 15.29 |
| Race group, African Am/African H., n=34, 24 | 256.4 ± 38.04 | 377.6 ± 45.25 |
| Race group, Asian, n=29, 25 | 258.5 ± 41.57 | 245.4 ± 44.36 |
| Race group, Other, n=31, 32 | 355.0 ± 39.84 | 240.7 ± 39.35 |
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value.
| Scores on a scale | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Week 4, n=359, 355 | 0.0111 ± 0.00326 | 0.0130 ± 0.00510 |
| Week 24, n=360, 358 | 0.0207 ± 0.00310 | 0.0203 ± 0.00347 |
| Week 48, n=360, 358 | 0.0189 ± 0.00362 | 0.0208 ± 0.00342 |
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
| Scores on a scale | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Change From Baseline in EQ-5D-5L Utility Score at Week 96 | 0.0168 ± 0.00339 | 0.0171 ± 0.00424 |
EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. MMRM was run on LOCF dataset. Baseline was the latest pre-dose assessment and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
| Scores on a scale | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Change From Baseline in EQ-5D-5L Utility Score at Week 144 | 0.0210 ± 0.00346 | 0.0131 ± 0.00441 |
EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value.
| Scores on a scale | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Week 4, n=358, 355 | 1.8 ± 0.50 | 3.1 ± 0.41 |
| Week 24, n=359, 358 | 3.9 ± 0.43 | 4.5 ± 0.48 |
| Week 48, n=359, 358 | 4.0 ± 0.43 | 4.6 ± 0.48 |
EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
| Scores on a scale | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase |
|---|---|---|
| Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96 | 4.4 ± 0.45 | 5.1 ± 0.52 |
EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.
| Scores on a scale | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase |
|---|---|---|
| Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144 | 4.8 ± 0.44 | 4.5 ± 0.51 |
Collected over All-cause mortality, SAEs and non-SAEs were collected up to Week 148 in Double-blind Phase + Open-label Phase and from Week 148 to Week 280 in Continuation Phase. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG + 3TC - Double-blind Phase + Open-label Phase | 2/360 (0.6%) | 39/360 (10.8%) | 273/360 (75.8%) |
| DTG + TDF/FTC - Double-blind Phase + Open-label Phase | 1/359 (0.3%) | 47/359 (13.1%) | 276/359 (76.9%) |
| DTG + 3TC - Continuation Phase | 0/252 (0%) | 9/252 (3.6%) | 45/252 (17.9%) |
| Event | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase | DTG + 3TC - Continuation Phase |
|---|---|---|---|
| Suicide attemptPsychiatric disorders | 5/360 | 2/359 | 0/252 |
| COVID-19Infections and infestations | 0/360 | 0/359 | 3/252 |
| Suicidal ideationPsychiatric disorders | 1/360 | 4/359 | 0/252 |
| Hepatitis AInfections and infestations | 3/360 | 3/359 | 1/252 |
| Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/360 | 3/359 | 0/252 |
| Cholecystitis acuteHepatobiliary disorders | 0/360 | 3/359 | 0/252 |
| PneumoniaInfections and infestations | 1/360 | 2/359 | 1/252 |
| SeizureNervous system disorders | 0/360 | 2/359 | 0/252 |
| CellulitisInfections and infestations | 0/360 | 2/359 | 0/252 |
| Acute hepatitis CInfections and infestations | 2/360 | 1/359 | 0/252 |
| Event | DTG + 3TC - Double-blind Phase + Open-label Phase | DTG + TDF/FTC - Double-blind Phase + Open-label Phase | DTG + 3TC - Continuation Phase |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 44/360 | 69/359 | 0/252 |
| DiarrhoeaGastrointestinal disorders | 49/360 | 53/359 | 0/252 |
| Upper respiratory tract infectionInfections and infestations | 47/360 | 28/359 | 7/252 |
| HeadacheNervous system disorders | 33/360 | 44/359 | 0/252 |
| PharyngitisInfections and infestations | 24/360 | 33/359 | 0/252 |
| NauseaGastrointestinal disorders | 16/360 | 31/359 | 0/252 |
| SyphilisInfections and infestations | 26/360 | 30/359 | 10/252 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 28/360 | 20/359 | 0/252 |
| Back painMusculoskeletal and connective tissue disorders | 27/360 | 23/359 | 0/252 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/360 | 25/359 | 0/252 |
Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.
| Age, Continuous(Years) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase | Total |
|---|---|---|---|
| Mean | 34.6 ± 10.72 | 34.4 ± 10.35 | 34.5 ± 10.53 |
| Sex: Female, Male(Participants) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase | Total |
|---|---|---|---|
| Female | 54 | 46 | 100 |
| Male | 306 | 313 | 619 |
| Race/Ethnicity, Customized(Participants) | DTG + 3TC - Double-blind Phase | DTG + TDF/FTC - Double-blind Phase | Total |
|---|---|---|---|
| American (Am) Indian or Alaska (Al.) native | 21 | 29 | 50 |
| Asian-Central/South Asian heritage (H.) | 0 | 3 | 3 |
| Asian - East Asian H. | 28 | 26 | 54 |
| Asian - South East Asian H. | 6 | 1 | 7 |
| Black or African Am | 51 | 35 | 86 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White (Wt)-Arabic/North African H. | 3 | 3 | 6 |
| Wt-Wt/Caucasian (Ca.)/European (Eu.) H. | 237 | 249 | 486 |
| Multiple | 14 | 12 | 26 |
Showing the first 100 of 105 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · viivhealthcare.com
Ran from Jul 2016 to primary completion in Apr 2018, 20 months.
Results were first posted in Apr 2019, 1 year after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamivudine